El-Kassas Mohamed, Villota-Rivas Marcela, Alswat Khalid A, AlNaamani Khalid M, Yilmaz Yusuf, Labidi Asma, Sanai Faisal M, Awad Abeer, Akroush Maisam W I, Alqahtani Saleh A, Elbadry Mohamed, Abdeen Nermeen, Henry Linda, Younossi Zobair M, Lazarus Jeffrey V, Elzouki Abdel-Naser
Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.
Steatotic Liver Disease Study Foundation in Middle East and North Africa (SLMENA), Cairo, Egypt.
Liver Int. 2025 Jun;45(6):e70108. doi: 10.1111/liv.70108.
BACKGROUND & AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health challenge, particularly in Middle East and North Africa (MENA) countries. This study aimed to establish a consensus-driven research and action agenda to address MASLD within the MENA region.
Following a global MASLD research and action agenda setting study, over two Delphi rounds (Rs), MENA region experts (R1 n = 112, R2 n = 104) indicated their level of agreement with and provided feedback on MASLD research and action priorities via Qualtrics XM. In R2, panellists also ranked the priorities, which were categorised across six domains: (1) the human and economic burden, (2) defining and implementing care models, (3) disease management, (4) education and awareness, (5) patient and community perspectives, and (6) leadership and policies for the MASLD public health agenda.
The consensus-built MASLD research and action priority agenda for the MENA region comprises 52 priorities. Combined agreement (i.e., 'agree' + 'somewhat agree') increased from 97.6% and 98.1% in R1 to 98.2% and 98.5% in R2 with the research (n = 30) and action (n = 22) priorities, respectively. The highest ranked research priorities included developing regional MASLD databases and validating non-invasive diagnostic tools. The highest ranked action priorities included taking steps to enhance the adoption of lifestyle interventions among people living with MASLD and improving disease knowledge among healthcare providers.
This region-specific agenda can help to guide research and optimise clinical practice, thereby improving the understanding, prevention, and management of MASLD, enhancing health outcomes and reducing its burden within the MENA region.
代谢功能障碍相关脂肪性肝病(MASLD)对健康构成的挑战日益严峻,在中东和北非(MENA)国家尤为如此。本研究旨在制定一项基于共识的研究与行动议程,以应对中东和北非地区的MASLD问题。
在一项全球MASLD研究与行动议程设定研究之后,经过两轮德尔菲法(R1有112名专家,R2有104名专家),中东和北非地区的专家通过Qualtrics XM表明他们对MASLD研究与行动优先事项的认同程度,并提供反馈。在第二轮中,小组成员还对优先事项进行了排序,这些优先事项分为六个领域:(1)人力和经济负担;(2)定义和实施护理模式;(3)疾病管理;(4)教育与认知;(5)患者和社区视角;(6)MASLD公共卫生议程的领导与政策。
为中东和北非地区建立的基于共识的MASLD研究与行动优先议程包括52项优先事项。对于研究优先事项(n = 30)和行动优先事项(n = 22),综合认同度(即“同意”+“ somewhat agree”)分别从第一轮的97.6%和98.1%提高到第二轮的98.2%和98.5%。排名最高的研究优先事项包括建立区域MASLD数据库和验证非侵入性诊断工具。排名最高的行动优先事项包括采取措施提高MASLD患者对生活方式干预的接受度,以及提高医疗服务提供者的疾病知识水平。
这一针对特定地区的议程有助于指导研究并优化临床实践,从而增进对MASLD的理解、预防和管理,改善健康结果,减轻其在中东和北非地区的负担。